Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment
Open Access
- 13 December 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (1) , 116-126
Abstract
By screening a drug library comprising FDA approved compounds, we discovered a potent interaction between the antifungal agent haloprogin and the experimental organometallic drug RAPTA-T, to synergistically induce cancer cell killing. The combination of these two small molecules, even at low doses, elicited an improved therapeutic response on tumor growth over either agent alone or the current treatment used in the clinic in the highly aggressive syngeneic B16F10 melanoma tumor model, where classical cytotoxic chemotherapeutic agents show little efficacy. The combination with the repurposed chemodrug haloprogin provides the basis for a new powerful treatment option for cutaneous melanoma. Importantly, because synergistic induction of tumor cell death is achieved with low individual drug doses, and cellular targets for RAPTA-T are different from those of classical chemotherapeutic drugs, a therapeutic strategy based on this approach could avoid toxicities and potentially resistance mechanisms, and could even inhibit metastatic progression.Keywords
This publication has 50 references indexed in Scilit:
- NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical applicationChemical Science, 2014
- DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical BiologyChemistry & Biology, 2013
- A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsCarcinogenesis, 2013
- Toxicities of anticancer drugs and its managementInternational Journal of Basic & Clinical Pharmacology, 2012
- Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339JBIC Journal of Biological Inorganic Chemistry, 2010
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Chemotherapy and the war on cancerNature Reviews Cancer, 2005
- Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in ratsJournal of Cancer Research and Clinical Oncology, 1992